{"title":"一名酒精相关性肝病患者的重症戊型肝炎病毒基因 3b 型:病例报告","authors":"Tatsuo Kanda, Shuhei Arima, Reina Sasaki-Tanaka, Mai Totsuka, Masayuki Honda, Ryota Masuzaki, Naoki Matsumoto, Masahiro Ogawa, Masaharu Takahashi, Hiroaki Okamoto, Hirofumi Kogure","doi":"10.3892/mi.2024.146","DOIUrl":null,"url":null,"abstract":". Hepatitis E virus (HEV) infection occasion‑ ally causes acute‑on‑chronic liver failure in patients with alcohol‑associated cirrhosis. These reports have been published mainly from highly HEV genotype 1‑endemic countries. The present study describes the case of a patient with severe HEV genotype 3b infection and alcohol‑associated liver disease. A male patient in his 70s who consumed alcohol, and who had begun consuming alcohol at the age of 12, had high levels of alanine aminotransferase (ALT) and total bilirubin. The peak levels of ALT and total bilirubin were 1,067 IU/l and 26.3 mg/dl, respectively. A computed tomography scan revealed an atrophic liver. Upon admission, both anti‑HEV immunoglobulin A and HEV RNA were positive, and his HEV was genotype 3b. He also had chronic kidney disease, as his estimated glomerular filtration rate was <45 ml/min/1.73 m 2 , and ribavirin could not be used. The abnormal levels of the liver function parameters of the patient gradually improved due to conservative treatment, and he was discharged on day 43. On the whole, the present study demonstrates that careful attention should be paid to patients with viral hepatitis, including hepatitis E, when alcohol‑associated liver disease is present. Novel anti‑HEV drugs need to be developed for severe HEV infections with chronic kidney disease.","PeriodicalId":74161,"journal":{"name":"Medicine international","volume":"10 7","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Severe hepatitis E virus genotype 3b in a patient with alcohol‑associated liver disease: A case report\",\"authors\":\"Tatsuo Kanda, Shuhei Arima, Reina Sasaki-Tanaka, Mai Totsuka, Masayuki Honda, Ryota Masuzaki, Naoki Matsumoto, Masahiro Ogawa, Masaharu Takahashi, Hiroaki Okamoto, Hirofumi Kogure\",\"doi\":\"10.3892/mi.2024.146\",\"DOIUrl\":null,\"url\":null,\"abstract\":\". Hepatitis E virus (HEV) infection occasion‑ ally causes acute‑on‑chronic liver failure in patients with alcohol‑associated cirrhosis. These reports have been published mainly from highly HEV genotype 1‑endemic countries. The present study describes the case of a patient with severe HEV genotype 3b infection and alcohol‑associated liver disease. A male patient in his 70s who consumed alcohol, and who had begun consuming alcohol at the age of 12, had high levels of alanine aminotransferase (ALT) and total bilirubin. The peak levels of ALT and total bilirubin were 1,067 IU/l and 26.3 mg/dl, respectively. A computed tomography scan revealed an atrophic liver. Upon admission, both anti‑HEV immunoglobulin A and HEV RNA were positive, and his HEV was genotype 3b. He also had chronic kidney disease, as his estimated glomerular filtration rate was <45 ml/min/1.73 m 2 , and ribavirin could not be used. The abnormal levels of the liver function parameters of the patient gradually improved due to conservative treatment, and he was discharged on day 43. On the whole, the present study demonstrates that careful attention should be paid to patients with viral hepatitis, including hepatitis E, when alcohol‑associated liver disease is present. Novel anti‑HEV drugs need to be developed for severe HEV infections with chronic kidney disease.\",\"PeriodicalId\":74161,\"journal\":{\"name\":\"Medicine international\",\"volume\":\"10 7\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medicine international\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3892/mi.2024.146\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicine international","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3892/mi.2024.146","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
.戊型肝炎病毒(HEV)感染偶尔会导致酒精相关性肝硬化患者出现急性-慢性肝功能衰竭。这些报告主要发表于戊型肝炎病毒基因 1 型高度流行的国家。本研究描述了一例严重 HEV 基因型 3b 感染和酒精相关性肝病患者的病例。一名 70 多岁的男性患者自 12 岁开始饮酒,丙氨酸氨基转移酶(ALT)和总胆红素水平较高。谷丙转氨酶和总胆红素的峰值分别为 1,067 IU/l 和 26.3 mg/dl。计算机断层扫描显示肝脏萎缩。入院时,抗 HEV 免疫球蛋白 A 和 HEV RNA 均呈阳性,他的 HEV 基因型为 3b。他还患有慢性肾病,估计肾小球滤过率<45毫升/分钟/1.73米2,因此不能使用利巴韦林。经过保守治疗,患者肝功能指标的异常水平逐渐改善,并于第 43 天出院。总之,本研究表明,当酒精相关性肝病出现时,应谨慎关注包括戊型肝炎在内的病毒性肝炎患者。对于伴有慢性肾病的严重戊型肝炎病毒感染,需要开发新型抗戊型肝炎病毒药物。
Severe hepatitis E virus genotype 3b in a patient with alcohol‑associated liver disease: A case report
. Hepatitis E virus (HEV) infection occasion‑ ally causes acute‑on‑chronic liver failure in patients with alcohol‑associated cirrhosis. These reports have been published mainly from highly HEV genotype 1‑endemic countries. The present study describes the case of a patient with severe HEV genotype 3b infection and alcohol‑associated liver disease. A male patient in his 70s who consumed alcohol, and who had begun consuming alcohol at the age of 12, had high levels of alanine aminotransferase (ALT) and total bilirubin. The peak levels of ALT and total bilirubin were 1,067 IU/l and 26.3 mg/dl, respectively. A computed tomography scan revealed an atrophic liver. Upon admission, both anti‑HEV immunoglobulin A and HEV RNA were positive, and his HEV was genotype 3b. He also had chronic kidney disease, as his estimated glomerular filtration rate was <45 ml/min/1.73 m 2 , and ribavirin could not be used. The abnormal levels of the liver function parameters of the patient gradually improved due to conservative treatment, and he was discharged on day 43. On the whole, the present study demonstrates that careful attention should be paid to patients with viral hepatitis, including hepatitis E, when alcohol‑associated liver disease is present. Novel anti‑HEV drugs need to be developed for severe HEV infections with chronic kidney disease.